Study design (if review, criteria of inclusion for studies)
Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
Participants
Cystic Fibrosis - 12 Years and older (Child, Adult, Older Adult)
Interventions
Drug: ELX/TEZ/IVA|Drug: IVA|Drug: TEZ/IVA
Outcome measures
Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1) for ELX/TEZ/IVA group|Absolute change in sweat chloride (SwCl) for ELX/TEZ/IVA group|Absolute change in ppFEV1 for ELX/TEZ/IVA group compared to the control group|Absolute change in SwCl for ELX/TEZ/IVA group compared to the control group|Absolute change from baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score for ELX/TEZ/IVA group|Absolute change in CFQ-R respiratory domain score for ELX/TEZ/IVA group compared to the control group|Safety and tolerability as assessed by number of subjects with adverse events (AEs) and serious adverse events (SAEs)